Ribupatide
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Active, not recruiting · Enrollment 264
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Ribupatide: Dose 1 | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 2 | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 3 | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 4 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Ribupatide: Dose 1: endpoint not reported
- Ribupatide: Dose 2: endpoint not reported
- Ribupatide: Dose 3: endpoint not reported
- Ribupatide: Dose 4: endpoint not reported
- Placebo: endpoint not reported